Anti-inflammation Effect Of Peroxisome Proliferator-activated Receptor-γ (PPAR-γ) In Non-obese Diabetic Mice With Sjogren`s Syndrome

Objective: To investigate the anti-inflammation effect of peroxisome proliferator-activated receptor-y (PPAR-y) in non-obese diabetic mice (NOD mice) with Sjogren's syndrome.Methods: Twenty 8-weeks-old female NOD mice were randomly divided into 2 groups. Rosiglitazone and normal saline were administered in rosiglitazone group and control group respectively. At the age of 12 weeks and 15 weeks, we killed one mouse in rosiglitazone group and control group respectively, and the others were sacrificed at the age of 17 weeks. Blood were obtained by cardiac puncture, and minor salivary glands (MSG) were resected. The histopathological change was examined by H&E staining. The level of IL-1β, IL-4, IL-6 and TNF-αin serum were measured by ELISA. Real-time PCR was used to evaluate the mRNA expression level of IL-1β, IL-4, IL-6 and TNF-αin MSG.Results: Compared with the control group, the mice in rosiglitazone group showed that:①histopathological change was significantly ameliorated;②at the age of 17 weeks, the levels of IL-6 [(25.86±7.32) vs (37.41±11.34) pg/ml] and TNF-a [(56.88±22.19) vs (78.61±20.76) pg/ml] were significantly lower and the level of IL-4 [(25.76±12.65) vs (12.11±3.70) pg/ml] was significantly higher in serum (p<0.05);③the expression of TNF-a was significantly decreased and the expression of IL-4 was significantly increased in MSG (p<0.05).④The level of IL-1βin serum and the expression of IL-1βand IL-6 were not significantly different (p>0.05).Conclusion:PPAR-y can ameliorate Sjogren's syndrome on NOD mice effectively. The mechanism may be related to reduce Thl cytokines, and promote the direction of Th1/Th2 balance into Th2.